Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : New York pleads for more COVID-19 vaccine as daily U.S. death toll hits record

01/13/2021 | 03:26pm EST

NEW YORK, Jan 13 (Reuters) - As the United States recorded its highest single-day death toll since the coronavirus pandemic began nearly a year ago, New York Mayor Bill de Blasio on Wednesday said the city would fall short of its inoculation goals unless it could get more vaccine.

The mayor said short supplies were hampering New York City's efforts to increase its immunization campaign. His appeal comes as the country as a whole struggles to meet an overall goal, with vaccinations now running far behind a target of 20 million people by now.

"We need the federal government, the state government and the manufacturers to step up and get us more supply immediately,” de Blasio said at a briefing.

The country's most populous city is adding vaccination sites across its five boroughs, including its two Major League Baseball parks, and has succeeded in loosening restrictions on who is eligible for vaccination, de Blasio said.

New York is on track to inoculate 1 million of its more than 8 million residents by the end of the month, but only if it gets enough vaccine, he said.

"I confirmed with our healthcare team yesterday that even with normal supplies that we expect to have delivered next week, we will run out of vaccine at some point next week, unless we get a major new resupply," he added.

Nationwide, only about one-third of the 29.4 million doses distributed to states have been administered, according to data from the U.S. Centers for Disease Control and Prevention.

The U.S. Food and Drug Administration has authorized the vaccine from Pfizer and partner BioNTech SE and a second vaccine from Moderna Inc for emergency use. Both vaccines require two doses spaced a few weeks apart.

The chief science officer of Johnson & Johnson said the company is on track to roll out its single-shot coronavirus vaccine in March, and it plans to have clear data on how effective it is by the end of this month or early February.

In an interview with Reuters on Tuesday, Dr. Paul Stoffels also said J&J expected to meet its stated target of delivering 1 billion doses of its vaccine by the end of this year as the company ramps up production.

The country's struggle to inoculate its population comes as the number of people to die from the disease hit a daily record 4,336 on Tuesday, according to a Reuters tally.

That brought the number of U.S. COVID-19 casualties to 380,524, with the number of cases at 22.7 million by Tuesday night, more than any other country.

The widely cited model of the University of Washington's Institute for Health Metrics and Evaluation expects January to be the pandemic's deadliest month so far in the United States.

The virus is projected to take more than 108,000 lives this month before the death rate ebbs as more vaccine is administered, the IHME said. By April 1, it expects a death toll of 567,000.

On Tuesday, federal health officials agreed to release millions of COVID-19 vaccine doses the government had held back for second shots, and they urged states to offer them to all Americans over age 65 or with chronic health conditions.

U.S. Department of Health and Human Services Secretary Alex Azar said during a news briefing that the U.S. pace of inoculations has risen to 700,000 per day and is expected to rise to 1 million per day within a week to 10 days.

A leveling-off of the number of COVID-19 patients requiring hospitalization has emerged as an encouraging sign in the past week. (Reporting by Peter Szekely; additional reporting by Julie Steenhuysen in Chicago; Editing by Cynthia Osterman)


© Reuters 2021
All news about MODERNA, INC.
01/22PFIZER : Provinces doing 'extraordinary' job to avoid wasting doses of COVID-19 ..
AQ
01/2239.9 MLN DOSES OF COVID-19 VACCINES : U.s. cdc
RE
01/22CDC : 10 life-threatening reactions linked with Moderna COVID-19 vaccine
AQ
01/22MODERNA : Lucky few hit COVID-19 vaccine jackpot for rare extra doses
AQ
01/22MODERNA : Severe allergic reactions to Moderna vaccine appear rare -CDC report
RE
01/22AstraZeneca's initial EU delivery volumes of COVID-19 vaccine to fall short
RE
01/22MODERNA : BofA Securities Adjusts Moderna PT to $140 From $130, Maintains Neutra..
MT
01/22Where Our Current Covid-19 Vaccination Rate Will Take Us
DJ
01/22Studies of South African Coronavirus Strain Raise Concerns About Immune Respo..
DJ
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
More news
Financials (USD)
Sales 2020 512 M - -
Net income 2020 -571 M - -
Net cash 2020 2 597 M - -
P/E ratio 2020 -107x
Yield 2020 -
Capitalization 51 846 M 51 846 M -
EV / Sales 2020 96,2x
EV / Sales 2021 4,40x
Nbr of Employees 1 100
Free-Float 90,0%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 137,27 $
Last Close Price 131,02 $
Spread / Highest target 41,2%
Spread / Average Target 4,77%
Spread / Lowest Target -47,3%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.25.41%51 846
LONZA GROUP AG4.64%49 880
CELLTRION, INC.-13.65%38 701
IQVIA HOLDINGS INC.3.58%35 985
SEAGEN INC.4.35%33 607
HANGZHOU TIGERMED CONSULTING CO.,LTD13.79%23 361